Gene therapy for prostate cancer - Research and development of a new immuno-gene therapy

Katsumi Sasaki, Ryuta Tanimoto, Shin Ebara, Hiromi Kumon, Yasutomo Nasu, Masami Watanabe, Haruki Kaku, Hiroyuki Yanai

Research output: Contribution to journalArticle

Abstract

We have performed three clinical studies for prostate cancer at Okayama University Hospital. In the first study (Suicide gene therapy using adenovirus vector (ADV) expressing herpes simplex virus-thymidine kinase gene and Ganciclovir), 9 castration-resistant prostate cancer (CRPC) patients without metastasis were treated from 2001 to 2005, demonstrating the safety profile and some clinical responses. In the second study (Immunogene therapy using ADV expressing the Interleukin-12 gene), 10 CRPC patients with or without metastasis were treated from 2008, demonstrating the safety profile and some immuno-clinical responses. The latest study (Gene therapy creating cancer vaccine using ADV expressing reduced expression in immortalized cells; REIC/Dkk-3 gene, which mediates simultaneous induction of cancer-selective apoptosis and augmentation of anti-tumor immunity), was initiated in Jan., 2011. The study category includes 2 groups: A, CRPC; and B, newly diagnosed high-risk localized cancer with indication for surgical resection (Neo-adjuvant). Four CRPC patients and 9 neo-adjuvant patients have been entered into the study with an excellent safety profile. Patients treated with the intermediate vector dose demonstrated modest clinical and/or immunological effects, and an increased vector dose showed remarkable immuno-pathological effects. Ad/REIODkk-3, a revolutionary gene-based medicine creating a cancer vaccine, could be a promising treatment option for prostate cancer.

Original languageEnglish
Pages (from-to)197-202
Number of pages6
JournalNishinihon Journal of Urology
Volume74
Issue number4
Publication statusPublished - Apr 2012

Fingerprint

Genetic Therapy
Prostatic Neoplasms
Castration
Research
Adenoviridae
Cancer Vaccines
Safety
Genes
Neoplasm Metastasis
Neoplasms
Ganciclovir
Thymidine Kinase
Simplexvirus
Interleukin-12
Suicide
Immunity
Medicine
Apoptosis
Therapeutics

Keywords

  • Cancer vaccine
  • Gene therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Gene therapy for prostate cancer - Research and development of a new immuno-gene therapy. / Sasaki, Katsumi; Tanimoto, Ryuta; Ebara, Shin; Kumon, Hiromi; Nasu, Yasutomo; Watanabe, Masami; Kaku, Haruki; Yanai, Hiroyuki.

In: Nishinihon Journal of Urology, Vol. 74, No. 4, 04.2012, p. 197-202.

Research output: Contribution to journalArticle

@article{7ed15a1728794422a09cc18c221498cd,
title = "Gene therapy for prostate cancer - Research and development of a new immuno-gene therapy",
abstract = "We have performed three clinical studies for prostate cancer at Okayama University Hospital. In the first study (Suicide gene therapy using adenovirus vector (ADV) expressing herpes simplex virus-thymidine kinase gene and Ganciclovir), 9 castration-resistant prostate cancer (CRPC) patients without metastasis were treated from 2001 to 2005, demonstrating the safety profile and some clinical responses. In the second study (Immunogene therapy using ADV expressing the Interleukin-12 gene), 10 CRPC patients with or without metastasis were treated from 2008, demonstrating the safety profile and some immuno-clinical responses. The latest study (Gene therapy creating cancer vaccine using ADV expressing reduced expression in immortalized cells; REIC/Dkk-3 gene, which mediates simultaneous induction of cancer-selective apoptosis and augmentation of anti-tumor immunity), was initiated in Jan., 2011. The study category includes 2 groups: A, CRPC; and B, newly diagnosed high-risk localized cancer with indication for surgical resection (Neo-adjuvant). Four CRPC patients and 9 neo-adjuvant patients have been entered into the study with an excellent safety profile. Patients treated with the intermediate vector dose demonstrated modest clinical and/or immunological effects, and an increased vector dose showed remarkable immuno-pathological effects. Ad/REIODkk-3, a revolutionary gene-based medicine creating a cancer vaccine, could be a promising treatment option for prostate cancer.",
keywords = "Cancer vaccine, Gene therapy, Prostate cancer",
author = "Katsumi Sasaki and Ryuta Tanimoto and Shin Ebara and Hiromi Kumon and Yasutomo Nasu and Masami Watanabe and Haruki Kaku and Hiroyuki Yanai",
year = "2012",
month = "4",
language = "English",
volume = "74",
pages = "197--202",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "4",

}

TY - JOUR

T1 - Gene therapy for prostate cancer - Research and development of a new immuno-gene therapy

AU - Sasaki, Katsumi

AU - Tanimoto, Ryuta

AU - Ebara, Shin

AU - Kumon, Hiromi

AU - Nasu, Yasutomo

AU - Watanabe, Masami

AU - Kaku, Haruki

AU - Yanai, Hiroyuki

PY - 2012/4

Y1 - 2012/4

N2 - We have performed three clinical studies for prostate cancer at Okayama University Hospital. In the first study (Suicide gene therapy using adenovirus vector (ADV) expressing herpes simplex virus-thymidine kinase gene and Ganciclovir), 9 castration-resistant prostate cancer (CRPC) patients without metastasis were treated from 2001 to 2005, demonstrating the safety profile and some clinical responses. In the second study (Immunogene therapy using ADV expressing the Interleukin-12 gene), 10 CRPC patients with or without metastasis were treated from 2008, demonstrating the safety profile and some immuno-clinical responses. The latest study (Gene therapy creating cancer vaccine using ADV expressing reduced expression in immortalized cells; REIC/Dkk-3 gene, which mediates simultaneous induction of cancer-selective apoptosis and augmentation of anti-tumor immunity), was initiated in Jan., 2011. The study category includes 2 groups: A, CRPC; and B, newly diagnosed high-risk localized cancer with indication for surgical resection (Neo-adjuvant). Four CRPC patients and 9 neo-adjuvant patients have been entered into the study with an excellent safety profile. Patients treated with the intermediate vector dose demonstrated modest clinical and/or immunological effects, and an increased vector dose showed remarkable immuno-pathological effects. Ad/REIODkk-3, a revolutionary gene-based medicine creating a cancer vaccine, could be a promising treatment option for prostate cancer.

AB - We have performed three clinical studies for prostate cancer at Okayama University Hospital. In the first study (Suicide gene therapy using adenovirus vector (ADV) expressing herpes simplex virus-thymidine kinase gene and Ganciclovir), 9 castration-resistant prostate cancer (CRPC) patients without metastasis were treated from 2001 to 2005, demonstrating the safety profile and some clinical responses. In the second study (Immunogene therapy using ADV expressing the Interleukin-12 gene), 10 CRPC patients with or without metastasis were treated from 2008, demonstrating the safety profile and some immuno-clinical responses. The latest study (Gene therapy creating cancer vaccine using ADV expressing reduced expression in immortalized cells; REIC/Dkk-3 gene, which mediates simultaneous induction of cancer-selective apoptosis and augmentation of anti-tumor immunity), was initiated in Jan., 2011. The study category includes 2 groups: A, CRPC; and B, newly diagnosed high-risk localized cancer with indication for surgical resection (Neo-adjuvant). Four CRPC patients and 9 neo-adjuvant patients have been entered into the study with an excellent safety profile. Patients treated with the intermediate vector dose demonstrated modest clinical and/or immunological effects, and an increased vector dose showed remarkable immuno-pathological effects. Ad/REIODkk-3, a revolutionary gene-based medicine creating a cancer vaccine, could be a promising treatment option for prostate cancer.

KW - Cancer vaccine

KW - Gene therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84861133559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861133559&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 197

EP - 202

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 4

ER -